Pharmaceutical composition containing 1,1,3,5-substituted biuret compound

Abstract

An analgesic, anti-inflammatory or anti-pyretic composition containing 1,1,3,5-substituted biuret compound of the formula, ##STR1## wherein R.sup.1 is a lower alkyl group or a phenyl group; R.sup.2 is a lower alkyl group, a phenyl group or a substituted phenyl group having chlorine atom(s), methyl group(s) or methoxy group(s) as the substituent(s), further R.sup.1 and R.sup.2 may form a single ring containing one or two hetero atoms including the adjacent nitrogen atom; R.sup.3 is a hydrogen atom, a lower alkyl group or a phenyl group; R.sup.4 is a phenyl group, a substituted phenyl group having halogen atom(s), trifluoromethyl group(s), methyl group(s), methoxy group(s), dimethyl-amino group(s), nitro group(s), hydroxyl group(s), acetyl group(s), or methylthio group(s) as the substituent(s), a benzyl group, a cyclohexyl group or a lower alkyl group, as the active ingredient.

Description

The present invention relates to a pharmaceutical composition containing a 1,1,3,5-substituted biuret compound. More particularly, the present invention relates to an analgesic, anti-inflammatory or anti-pyretic composition containing 1,1,3,5-substituted biuret compound of the formula (1), ##STR2## wherein R.sup.1 is a lower alkyl group or a phenyl group; R.sup.2 is a lower alkyl group, a phenyl group or a substituted phenyl group having chlorine atom(s), methyl group(s), or methoxy group(s) as the substituent(s), further R.sup.1 and R.sup.2 may form a single ring containing one or two hetero atoms including the adjacent nitrogen atom, R.sup.3 is a hydrogen atom, a lower alkyl group or a phenyl group; R.sup.4 is a phenyl group, a substituted phenyl group having halogen atom(s), trifluoromethyl group(s), methyl group(s), methoxy group(s), dimethylamino group(s), nitro group(s), hydroxyl group(s), acetyl group(s) or methylthio group(s) as the substituent(s), a benzyl group, a cyclohexyl group or a lower alkyl group, as the active ingredient.

Hitherto, some of 1,1,3,5-substituted biuret compounds represented by the formula (1) are known. On the other hand, although the definitions of the substituents in the formula (1) are different, other substituted biuret compounds having the basic structure of the formula, ##STR3## which is common to the formula (1) are known.

There have been reported that some of such known substituted biuret compounds, especially the latter compounds having the above-mentioned basic structure, have hypotensive, sedative or anti-convulsive activity. However, the prior art has not been aware that either 1,1,3,5-substituted biuret compounds represented by the general formula (1) or other biuret compounds, having the above-mentioned basic structure which is common to the general formula (1), have analgesic, anti-inflammatory or anti-pyretic activity. [cf. British Pat. No. 1,096,006; U.S. Pat. No. 3,189,431 and J. Amer. Chem. Soc., 62, 1595 (1940)].

The present invention is base on the facts that the 1,1,3,5-substituted biuret compounds represented by the general formula have analgesic, anti-inflammatory or anti-pyretic activity.

The object of the present invention is to provide novel 1,1,3,5-substituted biuret compounds.

Another object of the present invention is to provide an analgesic, anti-inflammatory or anti-pyretic composition containing 1,1,3,5-substituted biuret compound as the active ingredient.

Among the 1,1,3,5-substituted biuret compounds of the formula (1), the following compounds are novel ones.

1,1-Dimethyl-5-(2-fluorophenyl)biuret 1,1-Dimethyl-5-(4-methoxyphenyl)biuret 1,1,3-Trimethyl-5-phenylbiuret 1,1,3-Trimethyl-5-(2-fluorophenyl)biuret 1,1,3-Trimethyl-5-(4-fluorophenyl)biuret 1,1,3-Trimethyl-5-(2,3,5,6-tetrafluorophenyl)biuret 1,1,3-Trimethyl-5-(2-chlorophenyl)biuret 1,1,3-Trimethyl-5-(3-chlorophenyl)biuret 1,1,3-Trimethyl-5-(4-chlorophenyl)biuret 1,1,3-Trimethyl-5-(2,4-dichlorophenyl)biuret 1,1,3-Trimethyl-5-(3,4-dichlorophenyl)biuret 1,1,3-Trimethyl-5-(2,6-dichlorophenyl)biuret 1,1,3-Trimethyl-5-(4-bromophenyl)biuret 1,1,3-Trimethyl-5-(2-trifluoromethylphenyl)biuret 1,1,3-Trimethyl-5-(3-trifluoromethylphenyl)biuret 1,1,3-Trimethyl-5-(4-dimethylaminophenyl)biuret 1,1,3-Trimethyl-5-(4-nitrophenyl)biuret 1,1,3-Trimethyl-5-(4-hydroxyphenyl)biuret 1,1,3-Trimethyl-5-(2-methoxyphenyl)biuret 1,1,3-Trimethyl-5-(4-methoxyphenyl)biuret 1,1,3-Trimethyl-5-(3,4-dimethoxyphenyl)biuret 1,1,3-Trimethyl-5-(3,4,5-trimethoxyphenyl)biuret 1,1,3-Trimethyl-5-(2-methylphenyl)biuret 1,1,3-Trimethyl-5-(3-methylphenyl)biuret 1,1,3-Trimethyl-5-(4-methylphenyl)biuret 1,1,3-Trimethyl-5-(2,3-dimethylphenyl)biuret 1,1,3-Trimethyl-5-(3,4-dimethylphenyl)biuret 1,1,3-Trimethyl-5-(2,6-dimethylphenyl)biuret 1,1,3-Trimethyl-5-(2-methyl-3-chlorophenyl)biuret 1,1,3-Trimethyl-5-(4-acetylphenyl)biuret 1,1,3-Trimethyl-5-(4-methylthiophenyl)biuret 1,1,3-Trimethyl-5-cyclohexylbiuret 1,1-Dimethyl-3-ethyl-5-phenylbiuret 1,1-Dimethyl-3-n-propyl-5-phenylbiuret 1,1-Dimethyl-3-n-butyl-5-phenylbiuret 1,1,5-Trimethyl-3-phenylbiuret 1,1-Dimethyl-3-phenyl-5-n-propylbiuret 1,1-Dimethyl-3-phenyl-5-cyclohexylbiuret 1-Methyl-1-ethyl-5-phenylbiuret 1-Methyl-1-ethyl-5-benzylbiuret 1,3-Dimethyl-1-ethyl-5-phenylbiuret 1,3-Dimethyl-1-n-propyl-5-phenylbiuret 1-Methyl-1-n-butyl-5-phenylbiuret 1,3-Dimethyl-1-n-butyl-5-phenylbiuret 1,5-Dimethyl-1-phenylbiuret 1-Methyl-1-phenyl-5-ethylbiuret 1-Methyl-1-phenyl-5-n-propylbiuret 1-Methyl-1-phenyl-5-n-butylbiuret 1,3-Dimethyl-1-phenyl-5-ethylbiuret 1,3-Dimethyl-1-phenyl-5-n-propylbiuret 1,3-Dimethyl-1-phenyl-5-isopropylbiuret 1,1-Diethyl-3-methyl-5-phenylbiuret 1-Ethyl-1-phenyl-3,5-dimethylbiuret 1-Ethyl-1-(2-chlorophenyl)-3,5-dimethylbiuret 1-Ethyl-1-(4-chlorophenyl)-3,5-dimethylbiuret 1-Ethyl-1-(4-methoxyphenyl)-3,5-dimethylbiuret 1-Ethyl-1-(4-methoxyphenyl)-3,5-dimethylbiuret 1-n-Propyl-1-phenyl-3,5-dimethylbiuret 1-n-Butyl-1-phenyl-3,5-dimethylbiuret 1,1-Diphenyl-3,5-dimethylbiuret 1,1-Ethylene-3-methyl-5-phenylbiuret 1,1-Tetramethylene-5-phenylbiuret 1,1-Tetramethylene-3-methyl-5-phenylbiuret 1,1-Pentamethylene-5-phenylbiuret 1,1-Pentamethylene-3-methyl-5-phenylbiuret 1,1-(3-Oxapentamethylene)-5-phenylbiuret 1,1-(3-Oxapentamethylene)-3,5-dimethylbiuret 1,1-(3-Oxapentamethylene)-3-methyl-5-phenylbiuret

The 1,1,3,5-substituted biuret compound of the formula (1) can be prepared by any processes shown below.

REACTION PROCESS--A

Reaction of an urea compound of the formula (2) with an isocyanate of the formula (3) to obtain the 1,1,3,5-substituted biuret compound of the formula (1) as follows: ##STR4## This reaction process-A is actually classified to the following three methods.

REACTION PROCESS--A-1

The reaction of the urea compound (2) with the isocyanate compound of (3) is carried out in the absence or presence of a solvent. The solvent used in this reaction is not subjected to any specific restriction and any known inert type which gives no adverse effect to the reaction can be used. Among the examples of the solvents are ethers such as ether, dioxane, tetrahydrofuran and the like; halogenated lower alkanes such as methylene chloride, chloroform, carbon tetrachloride and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like. The ratio of amount of the urea compound (2) and the isocyanate compound (3) in this reaction is not subjected to any specific restriction and may be suitably selected from a wide range, and usually, it is desirable that they are used in equimolar quantity respectively. The reaction temperature is also not subjected to any particular restriction and may be suitably selected from a wide range, and usually the reaction can advantageously be carried out at a room temperature to the boiling point of the solvent used. The thus obtained 1,1,3,5-substituted biuret compound (1) can be isolated by usual separation means.

REACTION PROCESS--A-2

The reaction of the urea compound (2) with the isocyanate (3) is carried out in the presence of a catalyst in a solvent. As to the catalyst, basic catalysts such as sodium hydride, sodium amide and the like can be used. The solvent is not subjected to any specific restriction and any known type which gives no adverse effect to the reaction can be used. Among the examples of the solvents, ethers such as ether, dioxane, tetrahydrofuran and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like can be used. The ratio of amount of the urea compound (2) and the isocyanate compound (3) may be selected from a wide range, and usually it is desirable that they are used in equimolar quantity respectively. The amount of catalyst may also be selected from a wide range. The reaction temperature may also be selected from a wide range, and usually the reaction can advantageously be carried out at from -20.degree. C. to a room temperature. The thus formed, 1,1,3,5-substituted biuret compound (1) can be isolated by usual separation means.

REACTION PROCESS--A-3

The reaction of the urea compound (2) with the isocyanate compound (3) is carried out in the presence of a Lewis acid in a solvent. At to the Lewis acid, anhydrous aluminium chloride, anhydrous stannic chloride, titanium tetrachloride and the like can be used. The solvent is not subjected to any specific restriction and any known inert type which gives no adverse effect to the reaction can be used. Among the examples of the solvents, halogenated lower alkanes such as chloroform, methylene chloride, carbon tetrachloride and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like can be used. The ratio of amounts of the urea compound (2), the isocyanate compound (3) and the Lewis acid may be selected from a wide range, and usually, it is desirable that they are used in equimolar quantity respectively. The reaction temperature may also be selected from a wide range, and usually the reaction can advantageously be carried out at -20.degree. C. to a room temperature. The 1,1,3,5-substituted biuret compound (1) is formed as a complex with the Lewis acid, and a free form thereof can easily be obtained by treating the complex with a diluted mineral acid such as a diluted hydrochloric acid or a diluted sulfuric acid at a room temperature under stirring condition.

REACTION PROCESS--B

Reaction of an allophanoyl chloride of the formula (4) with an amine of the formula (5) to obtain the 1,1,3,5-substituted biuret compound of the formula (1) is shown as follows: ##STR5## The reaction may usually be carried out in a solvent. The solvent is not subjected to any specific restriction and any known inert type which gives no adverse effect to the reaction can be used. Among the examples of the solvents, halogenated lower alkanes such as methylene chloride, chloroform, carbon tetrachloride and the like; aromatic hydrocarbons such as benzene, toluene, xylene and the like may be used. If necessary, basic compounds such as trialkylamines, pyridine bases and the like may be used as suitable condensation agent. The ratio of amounts of the allophanoyl chloride (4) and the amine (5) may suitably be selected from a wide range, and usually, it is desirable that the amine (5) is used in equimolar to 2 times the molar quantity of the allophanoyl chloride (4). The reaction temperature may also be selected from a wide range, and the reaction can advantageously be carried out in the range of from -20.degree. to +50.degree. C. Thus formed 1,1,3,5-substituted biuret compound (1) can easily be isolated by usual separation means.

REACTION PROCESS C

Reaction of a 1,3-diazetidine-2,4-diene of the formula (6) with an amine of the formula (7) to obtain 1,1,3,5-substituted biuret compound of the formula (1) is shown as follows: ##STR6## This reaction may usually be carried out in a solvent. The solvent used in this reaction is not subjected to any specific restriction and any known inert type which gives no adverse effect to the reaction can be used. Generally, water, aceton, acetonitrile and the like may be used as the solvent. The ratio of amounts of the 1,3-diazetidine-2,4-dione (6) and the amine (7) in this reaction is not subjected to any specific restriction and may be suitably selected from a wide range, and usually, it is desirable that the amine (7) is used in equimolar to 2 times the molar quantity of the 1,3-diazetidine-2,4-dione (6). The reaction temperature is also not subjected to any particular restriction, and the reaction can advantageously be carried out at a room temperature to about 100.degree. C. The thus formed 1,1,3,5-substituted biuret compound of the formula (1) can be isolated by usual separation means.

Most of the 1,1,3,5-substituted biuret compounds of the formula (1) of the present invention [that is, all compounds, except those of formula (1') below] have analgesic, anti-inflammatory and anti-pyretic activities. However, among of those compounds, 1,1,3,5-substituted biuret compounds of the formula (1'), ##STR7## wherein R.sup.1' is a lower alkyl group; R.sup.2' is a lower alkyl group, a phenyl group, a substituted phenyl group having chlorine atom(s) or methoxy group(s) as the substituent(s); further R.sup.1' and R.sup.2' may form a single ring containing one or two hetero atoms including the adjacent nitrogen atom; R.sup.3 is a hydrogen atom, a lower alkyl group or a phenyl group; R.sup.4' is a phenyl group, a substituted phenyl group having halogen atom(s), trifluoromethyl group(s), methyl group(s), methoxy group(s), dimethylamino group(s), nitro group(s) or acetyl group(s) as the substituent(s), a benzyl group, a cyclohexyl group or a lower alkyl group, have only anti-inflammatory activity.

The 1,1,3,5-substituted biuret compound of the formula (1) of the present invention can be administered in the range of from 10 to 2,000 mg per day, preferably from 50 to 1,000 mg per day, for an adult, as an analgesic, anti-inflammatory or anti-pyretic agent. The administration of the compound is carried out by dividing the above-mentioned daily dosage into 2 or 3 portions. Said dosage of the compound may be adjusted in consideration of the clinical conditions and age of the patient.

The administration may be carried out in the form of peroral preparation, injection preparations, suppository preparations for rectal use, topical preparations and the like.

An analgesic, anti-inflammatory or anti-pyretic composition containing the present 1,1,3,5-substituted biuret compound of the formula (1) is prepared and administered by formulating with conventional pharmaceutically acceptable carriers or excipients through a common method.

Peroral preparations such as tablets, capsules, granules, powders, etc. may contain excipients used generally in the art. Said excipients are exemplified such as calcium carbonate, calcium phasphates, starch, sucrose, lactose, talc, magnesium stearate, gelatine, polyvinylpyrrolidone, gum arabic, sarbitol, microcrystalline cellulose, polyethyleneglycol, carboxymethylcellulose, silica, polyvinylacetal diethylaminoacetate, hydroxypropyl methylcellulose, shellac, etc. Further, the tablets may be coated with a suitable coating by a common method known in the arts. Peroral liquid form preparations may be of aqueous or oily suspensions, syrups, elixiers and the like and are prepared by common methods. Injection preparations may be of aqueous or oily suspensions, powdery or lyophilyzed preparations which is dissolved upon use. These preparations may be prepared by a common method.

The present substituted biuret compound may be administered as a suppository composition for rectal use, which may be contain pharmaceutically acceptable carriers, known in the art, such as polyethylene glycols, lanoline, cacao butter, fatty acid triglycerides and the like.

As to preparations for topical use, the substituted biuret compound of the formula (1) of the present invention may be administered in the form of an ointment or cream which is prepared by formulating with a suitable ointment base and other additives by common method.

EXAMPLES OF THE INVENTION

The present invention is further explained in detail by illustrating examples of synthesis of the substituted biuret compounds in Table 1; and pharmacological tests including analgesic activity test, anti-inflammatory activity test and anti-pyretic activity test in Table 2 together with examples of pharmaceutical preparations.

EXAMPLE 1

Synthesis of 1-ethyl-1-methyl-5-phenylbiuret (Compound No. 43 in Table 1) by reaction process A-1

In 50 ml of anhydrous dioxane, 7.7 g (0.075 mole) of 1-ethyl-1-methyl-urea was dissolved, into this solution 8.9 g (0.075 mole) of phenylisocyanate was added dropwise under stirring condition. The reaction was continued at a room temperature for 15 hours, then the precipitate thus formed was obtained by filtration and recrystallized from ethanol to obtain 10.8 g (yield 65%) of 1-ethyl-1-methyl-5-phenylbiuret having a melting point of 157.degree.-159.degree. C.

EXAMPLE 2

Synthesis of 1-ethyl-1,3-dimethyl-5-phenylbiuret (Compound No. 45 in Table 1) by reaction process A-2

In 300 ml of anhydrous tetrahydrofuran, 2.9 g (0.06 mole) of sodium hydride (50% in oil) was added thereto. The mixture was cooled below 10.degree. C. and 7.0 g (0.06 mole) of 1-ethyl-1,3-dimethylurea was added to the mixture under stirring. The reaction was then continued at a room temperature for 15 hours. Next the reaction mixture was cooled below 0.degree. C. and 7.1 g (0.06 mole) of phenyl isocyanate was added dropwise with stirring. The reaction was continued at about 0.degree. C. for 3 hours, then the solvent was removed by distillation under reduced pressure to obtain a residue. Ice-water was added to the residue and 1 N-hydrochloric acid was added to make the mixture acidic, then extracted with chloroform. The extracted liquor was dried with anhydrous sodium sulfate and the solvent was removed by distillation under reduced pressure to obtain a residue. The residue was recrystallized from ethanol-petroleum ether to obtain 7.2 g (yield, 51%) of 1-ethyl-1,3-dimethyl-5-phenylbiuret having a melting point of 88.5.degree.-90.5.degree. C.

EXAMPLE 3

Synthesis of 1,5-dimethyl-1-phenylbiuret (Compound No. 49 in Table 1) by reaction process A-3

In 150 ml of anhydrous dichloromethane, 7.0 g (0.05 mole) of 1-methyl-1-phenylurea was dissolved and under cooling with ice-water, with stirring, 2.9 g (0.05 mole) of methyl isocyanate was poured thereinto and further 13.0 g (0.05 mole) of stannic chloride was added dropwise. The reaction was continued at a room temperature for 15 hours to form precipitates. The precipitates were obtained by filtration and 30 ml of 20% hydrochloric acid--60 ml of chloroform was added and stirred. The reaction was continued until the reaction mixture become transparent, then the chloroform layer was separated, and washed with water. The chloroform layer was dried with anhydrous sodium sulfate and the solvent was removed by distillation under a reduced pressure to obtain a residue. The residue was recrystallized from ether-petroleum ether to obtain 8.3 g (yield 80%) of 1,5-dimethyl-1-phenylbiuret having a melting point of 123.degree.-125.degree. C.

EXAMPLE 4

Synthesis of 1,1-diethyl-3-methyl-5-phenylbiuret (Compound No. 57 in Table 1) by reaction process A-3

In 300 ml of anhydrous dichloromethane, 13.0 g (0.1 mole) of 1,1-diethyl-3-methylurea and 12.0 g (0.1 mole) of phenylisocyanate were dissolved. Under cooling the mixture with stirring, 26.0 g (0.1 mole) of stannic chloride was added dropwise. The reaction was continued at a room temperature for 15 hours and the reaction mixture was treated by a procedure similar to that of mentioned in Example 1, and recrystallized from ethanol-petroleum ether to obtain 19.7 (yield 79%) of 1,1-diethyl-3-methyl-5-phenylbiuret having a melting point of 88.degree.-89.5.degree. C.

EXAMPLE 5

Synthesis of 1,1,3-trimethyl-5-phenylbiuret (Compound No. 6 in Table 1) by reaction process-B

In 50 ml of anhydrous tetrahydrofuran, 7.4 g (0.08 mole) of aniline was dissolved. The mixture was cooled below 0.degree. C., and a solution prepared by dissolving 6.4 g (0.04 mole) of 2,4,4-trimethylallophanoyl chloride in 10 ml of anhydrous tetrahydrofuran was added dropwise under stirring. The reaction was continued at a room temperature for 1 hour, then the solvent was removed by distillation under a reduced pressure, and water was added to form an insoluble matter. The insoluble matter was obtained by filtration and was recrystallized from ethanol to obtain 13.0 g (yield 73%) of 1,1,3-trimethyl-5-phenylbiuret having a melting point 89.5.degree.-90.5.degree. C.

EXAMPLE 6

Synthesis of 1-ethyl-3,5-dimethyl-1-phenylbiuret (Compound No. 58 in Table 1) by reaction process-B

In 30 ml of anhydrous ethyl ether, 6.2 g (0.2 mole) of methyl amine was dissolved and cooled below 0.degree. C. Then a solution prepared by dissolving 24.1 g (0.1 mole) of 4-ethyl-2-methyl-4-phenylallophanoyl chloride in 80 ml of anhydrous dichloroethane was added dropwise under stirring. The reaction was continued at a room temperature for 1 hour, the reaction mixture was washed with water and dried with anhydrous sodium sulfate. The solvent was removed by distillation to obtain a residue, and the residue was recrystallized from ether-petroleum ether to obtain 17.6 g (yield 75%) of 1-ethyl-3,5-dimethyl-1-phenylbiuret having a melting point of 57.degree.-58.degree. C.

EXAMPLE 7

Synethsis of 1,1-dimethyl-3,5-diphenylbiuret (Compound No. 42 in Table 1) by reaction process-C

In 30 ml of acetonitrile, 0.025 mole of 1,3-diphenyl-1,3-diazetidine-2,4-dione was added, then 4.5 ml (0.05 mole) of dimethylamine aqueous solution (50%) was added dropwise under stirring. The reaction was continued at 50.degree. C. for 0.5 hours and the solvent was removed by distillation under a reduced pressure to obtain a residue. The residue was recrystallized from ethanol to obtain 5.4 g (yield 76%) of 1,1-dimethyl-3,5-diphenylbiuret having a melting point of 105.degree.-107.degree. C.

In the following Table 1, there are mentioned the physico-chemical properties of 1,1,3,5-substituted biuret compounds of the formula (1) including the compounds prepared in Examples 1-7.

TABLE 1__________________________________________________________________________ Compound ##STR8## ReactionNo. R.sup.1 R.sup.2 R.sup.3 R.sup.4 process MP (.degree.C.)__________________________________________________________________________1* CH.sub.3 CH.sub.3 H ##STR9## A-1 180.5-1812 CH.sub.3 CH.sub.3 H ##STR10## A-1 182-185 (Sublimated)3* CH.sub.3 CH.sub.3 H ##STR11## A-1 212-213.54 CH.sub.3 CH.sub.3 H ##STR12## A-1 156-1585* CH.sub.3 CH.sub.3 H ##STR13## A-1 186-1906 CH.sub.3 CH.sub.3 CH.sub.3 ##STR14## B 89.5- 90.57 CH.sub.3 CH.sub.3 CH.sub.3 ##STR15## B 66.5-688 CH.sub.3 CH.sub.3 CH.sub.3 ##STR16## B 73.5-74.59 CH.sub.3 CH.sub.3 CH.sub.3 ##STR17## B 103.5-10510 CH.sub.3 CH.sub.3 CH.sub.3 ##STR18## A-2 89.5-9111 CH.sub.3 CH.sub.3 CH.sub.3 ##STR19## A-2 87-8912 CH.sub.3 CH.sub.3 CH.sub.3 ##STR20## A-2 94.5-9513 CH.sub.3 CH.sub.3 CH.sub.3 ##STR21## B 69.5-7014 CH.sub.3 CH.sub.3 CH.sub.3 ##STR22## B 123-12415 CH.sub.3 CH.sub.3 CH.sub.3 ##STR23## B 140-14116 CH.sub.3 CH.sub.3 CH.sub.3 ##STR24## B 105-10617 CH.sub.3 CH.sub.3 CH.sub.3 ##STR25## B 72-7318 CH.sub.3 CH.sub.3 CH.sub.3 ##STR26## B 69-69.519 CH.sub.3 CH.sub.3 CH.sub.3 ##STR27## B 124-12620 CH.sub.3 CH.sub.3 CH.sub.3 ##STR28## B 157-15921 CH.sub.3 CH.sub.3 CH.sub.3 ##STR29## B 119-12022 CH.sub.3 CH.sub.3 CH.sub.3 ##STR30## B 112-113.523 CH.sub.3 CH.sub.3 CH.sub.3 ##STR31## B 87.5-8924 CH.sub.3 CH.sub.3 CH.sub.3 ##STR32## B 96.5-98.525 CH.sub.3 CH.sub.3 CH.sub.3 ##STR33## B 133-13526 CH.sub.3 CH.sub.3 CH.sub.3 ##STR34## B 59.5-6027 CH.sub.3 CH.sub.3 CH.sub.3 ##STR35## B 98-9928 CH.sub.3 CH.sub.3 CH.sub.3 ##STR36## B 115-11729 CH.sub.3 CH.sub.3 CH.sub.3 ##STR37## B 104-10530 CH.sub.3 CH.sub.3 CH.sub.3 ##STR38## B 115-11731 CH.sub.3 CH.sub.3 CH.sub.3 ##STR39## B 102-10532 CH.sub.3 CH.sub.3 CH.sub.3 ##STR40## B 102-10333 CH.sub.3 CH.sub.3 CH.sub.3 ##STR41## B 110-11234 CH.sub.3 CH.sub.3 CH.sub.3 ##STR42## B 59-6135 CH.sub.3 CH.sub.3 CH.sub.3 ##STR43## B 79-8036 CH.sub.3 CH.sub.3 C.sub.2 H.sub.5 ##STR44## B 104.5-106.537 CH.sub.3 CH.sub.3 (CH.sub.2).sub.2 CH.sub.3 ##STR45## B 102-104.538 CH.sub.3 CH.sub.3 (CH.sub.2).sub.3 CH.sub.3 ##STR46## B 92-93.539 CH.sub.3 CH.sub.3 ##STR47## CH.sub.3 B 98-99.540 CH.sub.3 CH.sub.3 ##STR48## (CH.sub.2).sub.3 CH.sub.3 B Oily product41 CH.sub.3 CH.sub.3 ##STR49## ##STR50## B 73.5-7542* CH.sub.3 CH.sub.3 ##STR51## ##STR52## C 105-10743 CH.sub.3 C.sub.2 H.sub.5 H ##STR53## A-1 157-15944 CH.sub.3 C.sub.2 H.sub.5 H ##STR54## A-2 100-10145 CH.sub.3 C.sub.2 H.sub.5 CH.sub.3 ##STR55## A-2 88.5-90.546 CH.sub.3 (CH.sub.2).sub.2 CH.sub.3 CH.sub.3 ##STR56## A-2 63-6447 CH.sub.3 (CH.sub.2).sub.3 CH.sub.3 H ##STR57## A-1 68-7048 CH.sub.3 (CH.sub.2).sub.3 CH.sub.3 CH.sub.3 ##STR58## A-3 Oily product49 CH.sub.3 ##STR59## H CH.sub.3 A-3 123-12550 CH.sub.3 ##STR60## H C.sub.2 H.sub.5 A-3 68-7051 CH.sub.3 ##STR61## H (CH.sub.2).sub.2 CH.sub.3 A-3 28-3052 CH.sub.3 ##STR62## H (CH.sub.2).sub.3 CH.sub.3 A-3 45-4653* CH.sub.3 ##STR63## CH.sub.3 CH.sub.3 B 109-11054 CH.sub.3 ##STR64## CH.sub.3 C.sub.2 H.sub.5 B Oily product55 CH.sub.3 ##STR65## CH.sub.3 (CH.sub.2).sub.2 CH.sub.3 B Oily product56 CH.sub.3 ##STR66## CH.sub.3 CH(CH.sub.3).sub.2 B Oily product57 C.sub.2 H.sub.5 C.sub.2 H.sub.5 CH.sub.3 ##STR67## A-3 88-89.558 C.sub.2 H.sub.5 ##STR68## CH.sub.3 CH.sub.3 B 57-5859 C.sub.2 H.sub.5 ##STR69## CH.sub.3 CH.sub.3 B 82-8360 C.sub.2 H.sub.5 ##STR70## CH.sub.3 CH.sub.3 B Oily product61 C.sub.2 H.sub.5 ##STR71## CH.sub.3 CH.sub.3 B Oily product62 C.sub.2 H.sub.5 ##STR72## CH.sub.3 CH.sub.3 B Oily product63 (CH.sub.2).sub.2 CH.sub.3 ##STR73## CH.sub.3 CH.sub.3 A-2 60-6164 (CH.sub.2).sub.3 CH.sub.3 ##STR74## CH.sub.3 CH.sub.3 A-2 Oily product65 ##STR75## ##STR76## CH.sub.3 CH.sub.3 A-2 151-15266 ##STR77## CH.sub.3 ##STR78## B 109.5-110.567 ##STR79## H ##STR80## A-1 174.5-176.568 ##STR81## CH.sub.3 ##STR82## B 77-7869 ##STR83## H ##STR84## A-1 163-16570 ##STR85## CH.sub.3 ##STR86## B 57-5871 ##STR87## H ##STR88## A-1 196-19972 ##STR89## CH.sub.3 CH.sub.3 B Oily product73 ##STR90## CH.sub.3 ##STR91## B 122-123__________________________________________________________________________ Elemental analysis (%) Calculated Compound UV.lambda. .sub.max.sup.Cyclohexane Molecular (Found) No. m.mu. (.epsilon.) formula C H N__________________________________________________________________________ 1* 242.5(18700) C.sub.10 H.sub.13 N.sub.3 O.sub.2 57.96 6.32 20.28 (57.84) (6.56) (20.39) 2 240(21600) C.sub.10 H.sub.12 FN.sub.3 O.sub.2 53.33 5.37 18.66 (53.51) (5.51) (18.83) 3* 247(20900) C.sub.10 H.sub.12 ClN.sub.3 O.sub.2 49.70 5.00 17.39 (49.72) (5.01) (17.45) 4 249.5(20200) C.sub.11 H.sub. 15 N.sub.3 O.sub.3 55.69 6.37 17.71 (55.61) (6.41) (17.37) 5* 245(18300) C.sub.10 H.sub.15 N.sub.3 O.sub.2 59.71 6.83 18.99 (59.50) (6.83) (18.92) 6 245(17800) C.sub.11 H.sub.15 N.sub.3 O.sub.2 59.71 6.83 18.99 (59.79) (6.92) (18.75) 7 241.5(19200) C.sub.11 H.sub.14 FN.sub.3 O.sub.2 55.22 5.90 17.56 (55.28) (5.91) (17.42) 8 241.5(15800) C.sub.11 H.sub.14 FN.sub.3 O.sub.2 55.22 5.90 17.56 (55.17) (6.04) (17.39) 9 232(15600) C.sub.11 H.sub.11 F.sub.4 N.sub.3 O.sub.2 45.06 3.78 14.33 (44.87) (3.84) (14.11) 10 247(16400) C.sub.11 H.sub.14 ClN.sub.3 O.sub.2 51.70 5.52 16.43 (51.59) (5.59) (16.39) 11 247(19000) C.sub.11 H.sub.14 ClN.sub.3 O.sub.2 51.70 5.52 16.43 (51.46) (5.51) (16.23) 12 250(22700) C.sub.11 H.sub.14 ClN.sub.3 O.sub.2 51.70 5.52 16.43 (51.63) (5.56) (16.55) 13 253(23400) C.sub.11 H.sub.13 Cl.sub.2 N.sub.3 45.54.2 4.52 14.48 (45.46) (4.57) (14.47) 14 253(23900) C.sub.11 H.sub.13 Cl.sub.2 N.sub.3 O.sub. 2 45.54 4.52 14.48 (45.33) (4.52) (14.48) 15 235 sh. C.sub.11 H.sub.13 Cl.sub.2 N.sub.3 45.54.2 4.52 14.48 (45.58) (4.36) (14.56) 16 252(24500) C.sub.11 H.sub.14 BrN.sub.3 O.sub.2 44.02 4.70 14.00 (43.67) (4.73) (13.91) 17 244(16700) C.sub.12 H.sub.14 F.sub.3 N.sub.3 O.sub.2 49.83 4.88 14.53 (49.84) (4.89) (14.14) 18 245(21100) C.sub.12 H.sub.14 F.sub.3 N.sub.3 O.sub.2 49.83 4.88 14.53 (49.83) (4.64) (14.46) 19 273(20600) C.sub.13 H.sub.20 N.sub.4 O.sub.2 59.07 7.63 21.20 (59.32) (7.56) (21.08) 20 310(15400) C.sub.11 H.sub.14 N.sub.4 O.sub.4 49.62 5.30 21.04 (49.63) (5.33) (21.06) 21 253(12500) C.sub.11 H.sub.15 N.sub.3 O.sub.3 55.69 6.37 17.71 (55.87) (6.56) (17.42) 22 247(16000) C.sub.12 H.sub.17 N.sub.3 O.sub.3 57.36 6.82 16.72 (57.57) (6.86) (16.58) 23 250.5(17500) C.sub.12 H.sub.17 N.sub.3 O.sub.3 57.36 6.82 16.72 (57.49) (6.83) (16.50) 24 253.5(13100) C.sub.13 H.sub.19 N.sub.3 O.sub.4 55.50 6.81 14.94 (55.22) (6.94) (14.72) 25 256(14300) C.sub.14 H.sub.21 N.sub.3 O.sub. 54.01 6.80 13.50 (54.00) (7.09) (13.54) 26 246(15200) C.sub.12 H.sub.17 N.sub.3 O.sub.2 61.26 7.28 17.86 (61.28) (7.48) (17.76) 27 246(17100) C.sub.12 H.sub.17 N.sub.3 O.sub.2 61.26 7.28 17.86 (61.39) (7.43) (17.76) 28 247.5(18800) C.sub.12 H.sub.17 N.sub.3 O.sub.2 61.26 7.28 17.86 (61.38) (7.15) (17.69) 29 247(13100) C.sub.13 H.sub.19 N.sub.3 O.sub.2 62.63 7.68 16.85 (62.87) (7.96) (16.80) 30 248(25400) C.sub.13 H.sub.19 N.sub.3 O.sub.2 62.63 7.68 16.85 (62.71) (8.00) (16.67) 31 227 sh. C.sub.13 H.sub.19 N.sub.3 O.sub.2 62.63 7.68 16.85 (62.66) (7.75) (16.80) 32 247.5(15400) C.sub.12 H.sub.16 ClN.sub.3 O.sub.2 53.44 5.98 15.58 (53.20) (6.06) (15.58) 33 283(25800) C.sub.13 H.sub.17 N.sub.3 O.sub.3 59.30 6.51 15.96 (59.30) (6.65) (15.82) 34 282(20700) C.sub.12 H.sub.17 N.sub.3 O.sub.2 S 53.91 6.41 15.72 (53.72) (6.44) (15.90) 35 C.sub.11 H.sub.21 N.sub.3 O.sub.2 58.12 9.31 18.49 (57.95) (9.60) (18.15) 36 245(16800) C.sub.12 H.sub.17 N.sub.3 O.sub.2 61.26 7.28 17.86 (61.61) (7.55) (18.05) 37 245(17600) C.sub.13 H.sub.19 N.sub.3 O.sub.2. 61.52 7.75 16.56 1/4H.sub.2 O (61.51) (7.94) (16.65) 38 245(14100) C.sub.14 H.sub.21 N.sub.3 O.sub.2 63.86 8.04 15.96 (63.85) (8.47) (15.97) 39 230(7800) C.sub.11 H.sub.15 N.sub.3 O.sub.2 59.71 6.83 18.99 (59.70) (6.97) (18.60) 40 C.sub.14 H.sub.21 N.sub.3 O.sub.2 .circle.a 41 C.sub.16 H.sub.23 N.sub.3 O.sub.2 66.41 8.01 14.52 (66.32) (8.11) (14.36) 42* C.sub.16 H.sub.17 N.sub.3 O.sub.2 67.83 6.05 14.83 (67.83) (5.92) (14.67) 43 243(20800) C.sub.11 H.sub.15 N.sub.3 O.sub.2 59.71 6.83 18.99 (59.53) (6.60) (18.61) 44 C.sub.12 H.sub.17 N.sub.3 O.sub.2 61.26 7.28 17.86 (61.42) (7.44) (17.53) 45 244.5(13400) C.sub.12 H.sub.17 N.sub.3 O.sub.2 61.26 7.28 17.86 (61.25) (7.44) (17.61) 46 244(19200) C.sub.13 H.sub.19 N.sub.3 O.sub.2 62.63 7.68 16.85 (62.84) (7.65) (16.88) 47 240(19200) C.sub.13 H.sub.19 N.sub.3 O.sub.2 62.63 7.68 16.85 (62.59) (7.68) (16.65) 48 C.sub.14 H.sub.21 N.sub.3 O.sub.2 .circle.b 49 234(5500) C.sub.10 H.sub.13 N.sub.3 O.sub.2 57.96 6.32 20.28 (58.11) (6.48) (20.22) 50 236(5400) C.sub.11 H.sub.15 N.sub.3 O.sub.2 59.71 6.83 18.99 (59.55) (7.08) (19.02) 51 C.sub.12 H.sub.17 N.sub.3 O.sub.2 61.26 7.28 17.86 (61.13) (7.24) (17.92) 52 235(5700) C.sub.13 H.sub.19 N.sub.3 O.sub.2 62.63 7.68 16.85 (62.68) (7.83) (16.95) 53* 244(10300) C.sub.11 H.sub.15 N.sub.3 O.sub.2 59.71 6.83 18.99 (59.81) (6.96) (18.93) 54 C.sub.12 H.sub.17 N.sub.3 O.sub.2 .circle.c 55 C.sub.13 H.sub.19 N.sub.3 O.sub.2 .circle.d 56 C.sub.13 H.sub.19 N.sub.3 O.sub.2 .circle.e 57 244(18900) C.sub.13 H.sub.19 N.sub.3 O.sub.2 62.63 7.68 16.85 (62.71) (7.61) (16.86) 58 245.5(10200) C.sub.12 H.sub.17 N.sub.3 O.sub.2 61.26 7.28 17.86 (60.84) (7.34) (17.70) 59 244(8200) C.sub.12 H.sub.16 ClN.sub.3 O.sub.2 53.43 5.98 15.58 (53.68) (6.07) (15.44) 60 C.sub.12 H.sub.16 ClN.sub.3 O.sub.2 .circle.f 61 C.sub.13 H.sub.19 N.sub.3 O.sub.3 .circle.g 62 C.sub.13 H.sub.19 N.sub.3 O.sub.2 .circle.h 63 C.sub.13 H.sub.19 N.sub.3 O.sub.2 62.63 7.68 16.85 (62.60) (7.56) (16.76) 64 C.sub.14 H.sub.21 N.sub.3 O.sub.2 .circle.i 65 251(15500) C.sub.16 H.sub.17 N.sub.3 O.sub.2 67.83 6.05 14.83 (67.83) (6.18) (14.85) 66 248.5(15700) C.sub.11 H.sub.13 N.sub.3 O.sub.2 60.26 5.98 19.17 (60.29) (5.85) (19.08) 67 243(21400) C.sub.12 H.sub.15 N.sub.3 O.sub.2 61.79 6.48 18.01 (61.69) (6.69) (18.11) 68 245(19000) C.sub.13 H.sub.17 N.sub.3 O.sub.2 63.14 6.93 16.99 (63.15) (7.10) (17.06) 69 C.sub.13 H.sub.17 N.sub.3 O.sub.2 63.14 6.93 16.99 (63.20) (6.91) (17.10) 70 246(18600) C.sub.14 H.sub.19 N.sub.3 O.sub.2 64.35 7.33 16.08 (64.31) (7.42) (15.82) 71 C.sub.12 H.sub.15 N.sub.3 O.sub.3 57.82 6.06 16.85 (58.00) (6.10) (16.88) 72 C.sub.8 H.sub.15 N.sub.3 O.sub.3 .circle.j 73 246(18000) C.sub.13 H.sub.17 N.sub.3 O.sub.3 59.30 6.51 15.96 (59.28) (6.27) (15.93)__________________________________________________________________________

In Table 1, the compounds * marks are known compounds and thus the remaining compounds are novel. Further, in compounds Nos. 40, 48, 54, 55, 56, 60, 61, 62, 64 and 72, under column of Elementary analysis, a , b , c , d , e , f , g , h , i and j indicate the following data obtained by NMR and mass-spectrography methods in place of data obtained by elemental analysis.

.sup.a NMR(CDCl.sub.3) .delta.: 0.91 (3H, m, N.sub.1 --CH.sub.2 CH.sub.2 CH.sub.2 --CH.sub.3), 1.05-1.68 (4H, m, N.sub.1 --CH.sub.2 --CH.sub.2 CH.sub.2 --CH.sub.3), 2.82 ##STR92## 3.25 (2H, q, J=6.0 Hz, N.sub.1 --CH.sub.2 --CH.sub.2 CH.sub.2 CH.sub.3), 6.39 (1H, broad, N.sub.1 --H), 7.15-7.56 (5H, m, Ar--H), MS m/e: 263 (M.sup.+). .sup.b NMR(CDCl.sub.3) .delta.: 0.94 (3H, m, N.sub.1 --CH.sub.2 CH.sub.2 CH.sub.2 --CH.sub.3), 1.07-1.80 (4H, m, N.sub.1 --CH.sub.2 --CH.sub.2 CH.sub.2 --CH.sub.3), 2.90 (3H, s, N.sub.1 --CH.sub.3), 3.12 (3H, s, N.sub.3 --CH.sub.3), 3.24 (2H, q, J=8.0 Hz, N.sub.1 --CH.sub.2 --CH.sub.2 CH.sub.2 CH.sub.3), 6.85-7.51 (5H, m, Ar--H), 9.47 (1H, broad s, N.sub.5 --H). MS m/e: 263 (M.sup.+). .sup.c NMR(CDCl.sub.3) .delta.: 1.12 (3H, t, J=7.0 Hz, N.sub.1 --CH.sub.2 --CH.sub.3), 2.54 (3H, s, N.sub.3 --CH.sub.3), 3.23 (3H, s, N.sub.5 --CH.sub.3), 3.27 (2H, m J=7.0 Hz, N.sub.1 --CH.sub.2 --CH.sub.3), 6.96-7.45 (5H, m, Ar--H), 7.97 (1H, broad, N.sub.1 --H). MS m/e: 235 (M.sup.+). .sup.d NMR(CDCl.sub.3) .delta.: 0.91 (3H, t, J=7.0 Hz, N.sub.5 --CH.sub.2 CH.sub.2 --CH.sub.3), 1.52 (2H, m, J=7.0 Hz, N.sub.5 --CH.sub.2 --CH.sub.2 --CH.sub.3), 2.55 (3H, s, N.sub.3 --CH.sub.3), 3.24 (3H, s, N.sub.1 --CH.sub.3), 3.22 (2H, q, J=7.0 Hz, N.sub.5 --CH.sub.2 --CH.sub.2 CH.sub. 3), 6.90-7.40 (5H, m, Ar--H), 8.05 (1H, broad, N.sub.5 --H). MS m/e: 249 (M.sup.+). e NMR(CDCl.sub.3) .delta.: 1.14 (6H, d, J=7.0 Hz, --HC(CH.sub.3).sub.2), 2.54 (3H, s, N.sub.3 --CH.sub.3), 3.22 (3H, s, N.sub.1 --CH.sub.3), 3.90 (1H, m, J=7.0 Hz, N.sub.5 --CH(CH.sub.3).sub.2), 7.00-7.40 (5H, m, Ar--H), 7.94 (1H, broad d, N.sub.5 --H). MS m/e: 249 (M.sup.+). f NMR(CDCl.sub.3) .delta.: 1.10 (3H, t, J=7.0 Hz, N.sub.1 --CH.sub.2 --CH.sub.3), 2.58 (3H, s, N.sub.3 --CH.sub.3), 2.82 (3H, d, J=5.0 Hz, N.sub.5 --CH.sub.3), 3.68 (2H, q, J=7.0 Hz, N.sub.1 --CH.sub.2 --CH.sub.3), 6.82-7.49 (4H, m, Ar--H), 7.88 (1H, broad, N.sub.5 --H). MS m/e: 269 (M.sup.+). .sup.g NMR(CDCl.sub.3) .delta.: 1.10 (3H, t, J=7.0 Hz, N.sub.1 --CH.sub.2 --CH.sub.3), 2.53 (3H, s, N.sub.3 --CH.sub.3), 2.80 (3H, d, J=5.0 Hz, N.sub.5 --CH.sub.3), 3.64 (2H, q, J=7.0 Hz, N.sub.1 --CH.sub.2 --CH.sub.3). 3.75 (3H, s, O--CH.sub.3), 6.71-7.09 (4H, m, Ar--H), 7.85 (1H, broad, N.sub.5 --H). MS m/e: 265 (M.sup.+). .sup.h NMR(CDCl.sub.3) .delta.: 1.10 (3H, t, J=7.0 Hz, N.sub.1 --CH.sub.2 --CH.sub.3), 2.30 (3H, s, Ar--CH.sub.3), 2.53 (3H, s, N.sub.3 --CH.sub.3), 2.81 (3H, d, J=5.0 Hz, N.sub.5 --CH.sub.3), 3.67 (2H, q, J=7.0 Hz, N.sub.1 --CH.sub.2 --CH.sub.3), 6.75-7.25 (4H, m, Ar--H), 7.89 (1H, broad, N.sub.5 --H). MS m/e: 249 (M.sup.+). .sup.i NMR(CDCl.sub.3) .delta.: 0.85 (3H, m, J=6.0 Hz, N.sub.1 --CH.sub.2 CH.sub.2 CH.sub.2 --CH.sub.3), 1.02-1.85 (4H, m, N.sub.1 --CH.sub.2 --CH.sub.2 CH.sub.2 --CH.sub.3), 2.52 (3H, s, N.sub.3 --CH.sub.3), 2.81 (3H, d, J=4.0 Hz, N.sub.5 --CH.sub.3), 3.63 (2H, t, J=6.0 Hz, N.sub.1 --CH.sub.2 --CH.sub.2 CH.sub.2 CH.sub.3), 6.90-7.50 (5H, m, Ar--H), 7.93 (1H, broad, N.sub.5 --H). MS m/e: 263 (M.sup.+). .sup.j NMR(CDCl.sub.3) .delta.: 2.76 (3H, d, J=5.0 Hz, NH--CH.sub.3), 3.05 ##STR93## 3.20-3.78 (8H, m, morpholine ring protons), 7.18 (1H, broad, NH--CH.sub.3), MS m/e: 201 (M.sup.+).

Next, several tests for determining the pharmacological properties, in that acute toxicity, anti-pyretic activity, analgesic activity and anti-inflammatory activity of the present 1,1,3,5-substituted biuret compounds of the formula (1) were conducted and the test results are shown in Table (2). In the tests, each compounds to be tested was used as a suspension in 0.25% carboxymethylcellulose solution. Methods for testing are explained as follows:

1. Acute toxicity

The ddy strain of male mice (body weight, 20-25 g) were used as test animals. The mice were fasted overnight and the compound to be tested was administered orally. General symptom of the mouse after the administration was observed for 7 days. The lethal dose (mg/kg, body weight) of the test compound was determined in connection with the death number of mice/the number of mice tested. In Table 2, the values indicated with .DELTA. marks are 50% lethal dose, LD.sub.50 (mg/kg, body weight).

2. Anti-pyretic activity

According to the method reported by Tanabe [Folia Pharmacologia Japonica, Vol. 73, pp. 803 (1977)], the Wistar strain of male rats (150-180 g, body weight) were used as test animals. The rats were fasted overnight, and 1 ml/100 g (body weight) of 10% dry-yeast suspension were subcutaneously injected on the back of the rats. Five hours after the injection, the test compound was administered orally, then the body temperature of the rat was measured at time sequences. Anti-pyretic activity of the test compound was determined as the FI (febril index) by integrating pyrogenetic curve up to 4 hours after the administration of the test compound with time, and indicated as inhibitory ratio (%) shown by the following formula, ##EQU1##

3. Analgesic activity

(1) Acetic acid-induced stretching method

According to the method reported by Koster et al., [Fed. Proc., Vol. 18, pp. 412 (1959)], the ddy strain of male mice (body weight, 20-25 g) were used as test animals. The mice were fasted overnight, 100 mg/kg body weight of the test compound was administered orally, then 1 hour after the administration, 0.2 ml of 0.7% acetic acid solution was injected intraperitoneally. The acetic acid-induced stretching symptom of mouse was observed. Analgesic activity of the test compound was calculated as the inhibitory ratio (%). In Table 2, the values in parentheses show the data obtained from the test by using the dosage other than 100 mg/kg body weight. Further, the values indicated with .DELTA. marks show 50% effective dose, ED.sub.50 (mg/kg body weight).

(2) Haffner method

According to the modified method reported by Fujimura et. al., [Bulletin of the Institute for Chemical Research, Kyoto University, No. 25, pp. 36 (1951)], the ddy strain of male mice (body weight, 20-25 g) were used as test animals. The mice were fasted overnight, 100 mg/kg body weight of the test compound was administered orally, then 45 minutes after the administration, the threshold amount (1.5-2.5 mg/kg body weight) of morphine hydrochloride was injected subcutaneously. Then 1-hour pain reaction of the mouse caused by a clamp was observed. Analgesic activity of the test compound was calculated as the inhibitory ratio (%). In Table 2, the values in parentheses show the data obtained from the test by using the dosage other than 100 mg/kg body weight. Further, the values indicated with .DELTA. marks show 50% effective dose, ED.sub.50 (mg/kg body weight).

4. Anti-inflammatory activity

According to the method of acute carrageenin-induced inflammatory test [Folia Pharmacologia Japonica, Vol. 56, pp. 575 (1960)], the Wistar strain of male rats (body weight, 150-180 g) were used as test animals. The rats were fasted overnight, 100 mg/kg body weight of the test compound was administered orally, then 1 hour after the administration, 0.1 ml of 1% carrageenin solution, as the inflammation inducing agent, was injected subcutaneously to the hindpaw of the rat and the volume of the hindpaw was measured at time sequences, Anti-inflammatory activity of the test compound was calculated as inflammation inhibitory ratio (%) at 3 hours after the injection of inflammation inducing agent.

TABLE 2__________________________________________________________________________ Anti-Acute Analgesic activity (%) Anti-pyretic inflammatoryCompound toxicity Acetic acid-induced Haffner activity activityNo. (mg/kg) stretching method method (%) (%)__________________________________________________________________________ 1* 2000 - 0/4 50 50 42 (200 mg/kg) 2 2000 - 0/4 40 3* 2000 - 0/4 50 4 2000 - 0/4 75 50 43 5* 2000 - 0/4 25 23 (2 hours) 6 .sup..DELTA. 1709 .sup..DELTA. 75(43-132) .sup..DELTA. 68(52-88) 80 59 7 1000 - 1/4 62.5 75 76 63 2000 - 4/4 8 .sup..DELTA. 930 87.5 62.5 61 37 9 500 - 0/4 87.5 50 33 24 1000 - 4/410 2000 - 0/4 .sup..DELTA. 135(71-236) 37.5 66 3811 .sup..DELTA. 1481 62.5 75 43 30 (200 mg/kg) (2 hours)12 .sup..DELTA. 1200 .sup..DELTA. 12(4-36) .sup..DELTA. 20(11-35) 84 4713 1000 - 0/4 50 75 42 2000 - 3/414 1000 - 1/4 50 62.5 43 2000 - 3/415 .sup..DELTA. 1100 50 50 29 2516 .sup..DELTA. 1353 .sup..DELTA. 60(48-76) .sup..DELTA. 74(49-113) 103 48 (2 hours)17 1000 - 1/4 12.5 37.5 65 6618 1000 - 0/4 37.5 .sup..DELTA. 64(37-112) 62 32 2000 - 4/4 (2 hours)19 2000 - 0/4 62.5 50 26 32 (2 hours)20 500 - 2/4 100 50 26 3221 1000 - 0/4 37.5 12.5 2000 - 3/422 1000 - 0/4 37.5 50 13 35 2000 - 2/4 (2 hours)23 .sup..DELTA. 1800 .sup..DELTA. 39(21-73) .sup..DELTA. 80(42-153) 75 3324 1000 - 0/4 75 62.5 18 2000 - 4/425 500 - 0/4 .sup..DELTA. 38(18-80) 62.5 23 30 1000 - 2/426 .sup..DELTA. 1000 37.5 50 41 2927 2000 - 2/4 75 37.5 31 2828 2000 - 0/4 .sup..DELTA. 33(14- 78) .sup..DELTA. 80(42-152) 52 23 (2 hours)29 1000 - 1/4 50 25 40 2000 - 4/430 2000 - 1/4 87.5 .sup..DELTA. 86(57-129) 31 (60 mg/kg)31 .sup..DELTA. 595 75 37.5 6932 1000 - 1/4 75 25 45 2000 - 4/433 500 - 0/4 62.5 37.5 36 31 1000 - 4/4 (2 hours)34 1000 - 0/4 50 2000 - 4/435 .sup..DELTA. 1447 87.5 25 24 (200 mg/kg)36 1000 - 0/4 62.5 62.5 12 23 2000 - 3/437 2000 - 0/4 37.5 62.5 12 (200 mg/kg)38 1000 - 0/4 37.5 37.5 18 31 2000 - 3/4 (200 mg/kg)39 .sup..DELTA. 93 25 25 33 (50 mg/kg) (50 mg/kg) (25 mg/kg)40 1000 - 0/4 62.5 62.5 2000 - 1/4 (200 mg/kg)41 .sup..DELTA. 1276 50 62.5 (200 mg/kg) 42* 1000 - 0/4 62.5 50 14 34 2000 - 3/4 (200 mg/kg) (200 mg/kg)43 2000 - 0/4 50 12.5 72 (200 mg/kg) (200 mg/kg)44 .sup..DELTA. 1400 87.5 47 (200 mg/kg)45 .sup..DELTA. 1288 50 .sup..DELTA. 100(59-170) 49 34 (80 mg/kg)46 1000 - 1/4 75 37.5 44 26 2000 - 4/4 (60 mg/kg) (2 hours)47 2000 - 0/4 50 25 2048 1000 - 0/4 37.5 25 35 2000 - 3/449 .sup..DELTA. 1605 .sup..DELTA. 34(16-79) .sup..DELTA. 86(41-183) 84 3250 .sup..DELTA. 1960 50 37.5 90 3851 500 - 1/4 37.5 87.5 164 60 1000 - 2/452 1000 - 0/4 62.5 50 104 48 2000 - 3/4 53* .sup..DELTA. 1349 .sup..DELTA. 68(30-152) .sup..DELTA. 135(63-291) 108 7654 .sup..DELTA. 1350 37.5 75 58 5455 1000 - 1/4 .sup..DELTA. 80(44-147) .sup..DELTA. 90(60-134) 80 73 1500 - 4/456 .sup..DELTA. 1325 25 12.5 65 4757 2000 - 1/4 37.5 50 19 23 (200 mg/kg)58 .sup..DELTA. 1000 75 62.5 137 6059 .sup..DELTA. 810 37.5 12.5 64 51 (2 hours)60 1000 - 1/4 75 50 88 33 2000 - 3/461 .sup..DELTA. 1252 75 25 35 5262 .sup..DELTA. 1481 62.5 37.5 1863 1000 - 3/4 50 50 76 58 2000 - 4/464 500 - 1/4 25 37.5 50 43 1000 - 2/465 1000 - 1/4 12.5 50 2000 - 4/466 250 - 2/4 62.5 25 28 500 - 4/467 2000 - 0/4 50 37.5 3368 2000 - 2/4 75 2469 2000 - 0/4 50 .sup..DELTA. 115(66-200) (200 mg/kg)70 .sup..DELTA. 515 62.5 37.571 2000 - 0/4 40 50 23 (200 mg/kg) (200 mg/kg) (200 mg/kg)72 2000 - 0/4 50 2573 2000 - 0/4 50 25 17__________________________________________________________________________

The followings are examples of preparations for analgesic, anti-pyretic or anti-inflammatory composition containing 1,1,3,5-substituted biuret compound of the formula (1) as the active ingredient.

______________________________________Preparation 1Ingredients Amount (mg)______________________________________1,1,3-Trimethyl-5-phenylbiuret(Compound No. 6) 200Lactose 500Corn starch 280Hydroxypropylcellulose 20To make one package contains 1,000______________________________________

By using the ingredients in the above-mentioned formulation, granular preparation is prepared by common method.

______________________________________Preparation 2Ingredients Amount (mg)______________________________________1,1,3-Trimethyl-5-(4-chloro-phenyl)biuret(Compound No. 12) 100Lactose 85Crystalline cellulose 50Hydroxypropylstarch 30Talc 4Magnesium stearate 1To make one tablet contains 270______________________________________

By using the ingredients in the above-mentioned formulation, tablet preparation is prepared by common method.

______________________________________Preparation 3Ingredients Amount (mg)______________________________________1,1,3-Trimethyl-5-(4-bromophenyl)-biuret(Compound No. 16) 100Lactose 50Potate starch 50Crystalline cellulose 109Magnesium stearate 1To make one capsule contains 310______________________________________

By using the ingredients in the above-mentioned formulation, a capsule preparation is prepared by common method.

______________________________________Preparation 4Ingredients Amount (mg)______________________________________1,1,3-Trimethyl-5-(4-methoxy-phenyl)biuret(Compound No. 23) 200Lactose 100Crystalline cellulose 98Magnesium stearate 2To make one capsule contains 400______________________________________

By using the ingredients in the above-mentioned formulation, a capsule preparation is prepared by common method.

______________________________________Preparation 5Ingredients Amounts (mg)______________________________________1,1,3-Trimethyl-5-(4-methyl-phenyl)biuret(Compound No. 28) 250Witepzol W-35(A trade name for a suppositorybase material manufactured byand sold from Dynamite NobelCompany.) 750To make one suppositorycontains 1,000______________________________________

By using the ingredients in the above-mentioned formulation, a suppository preparation is prepared by common method.

______________________________________Preparation 6Ingredients Amounts (mg)______________________________________1,1,3-Trimethyl-5-(3,4-dimethyl-phenyl)biuret(Compound No. 30) 100Sodium chloride 16Distilled water for injection q.s.To make one ampule contains 2 ml______________________________________

By using the ingredients in the above-mentioned formulation, an injection preparation (ampule) is prepared by common method.

______________________________________Preparation 7Ingredients Amounts (g)______________________________________1,3,5-Trimethyl-1-phenylbiuret(Compound No. 53) 2.0White vaseline 23.0Stearyl alcohol 22.0Propylene glycol 12.0Sodium laurylsulfate 1.5Ethyl p-oxybenzoate 0.025Propyl p-oxybenzoete 0.015Purified water q.s.To make the whole 100______________________________________

By using the ingredients in the above-mentioned formulation, an ointment preparation is prepared by common method.

______________________________________Preparation 8Ingredients Amount (mg)______________________________________1,1,3-Trimethyl-5-(2-fluoro-phenyl)biuret(Compound No. 7) 100Lactose 85Crystalline cellulose 50Hydroxypropylstarch 30Talc 4Magnesium stearate 1To make one tablet contains 270______________________________________

By using the ingredients in the above-mentioned formulation, tablet preparation is prepared by common method.

______________________________________Preparation 9Ingredients Amount (mg)______________________________________1,1,3-Trimethyl-5-(2-trifluoro-methylphenyl)biuret(Compound No. 17) 100Lactose 50Potate starch 50Crystalline cellulose 109Magnesium stearate 1To make one capsule contains 310______________________________________

By using the ingredients in the above-mentioned formulation, a capsule preparation is prepared by common method.

______________________________________Preparation 10Ingredients Amounts (mg)______________________________________1,3,5-Trimethyl-1-phenylbiuret(Compound No. 53) 200Lactose 100Crystalline cellulose 98Magnesium stearate 2To make one capsule contains 400______________________________________

By using the ingredients in the above-mentioned formulation, a capsule preparation is prepared by common method.

______________________________________Preparation 11Ingredients Amounts (mg)______________________________________1,3-Dimethyl-5-ethyl-1-phenylbiuret(compound No. 54) 250Witepzol W-35(A trade name for a suppositorybase material manufactured byand sold from Dynamite NobelCompany.) 750To make one suppositorycontains 1,000______________________________________

By using the ingredients in the above-mentioned formulation, a suppository preparation is prepared by common method.

______________________________________Preparation 12Ingredients Amounts (mg)______________________________________1,3-Dimethyl-5-n-propyl-1-phenylbiuret(Compound No. 55) 100Sodium chloride 16Distilled water for injection q.s.To make one ampule contains 2 ml______________________________________

By using the ingredients in the above-mentioned formulation, an injection preparation (ampule) is prepared by common method.

______________________________________Preparation 13Ingredients Amount (g)______________________________________1-Ethyl-3,5-dimethyl-1-(4-methoxyphenyl)biuret(Compound No. 61) 2.0White vaseline 23.0Stearyl alcohol 22.0Propylene glycol 12.0Sodium laurylsulfate 1.5Ethyl p-oxybenzoete 0.025Propyl p-oxybenzoete 0.015Purified water q.s.To make the whole 100______________________________________

By using the ingredients in the above-mentioned formulation, an ointment preparation is prepared by common method.

Claims

1. An analgesic, anti-inflammatory or anti-pyretic composition in the form of a tablet, capsule, granules, powder, injection preparation, suppository preparations, topical ointment or cream or per oral syrup, elixir or oily suspension containing as the active ingredient an effective amount of 1,1,3,5-substituted biuret compound of the formula (1), ##STR94## wherein R.sup.1 is a lower alkyl group or a phenyl group; R.sup.2 is a lower alkyl group, a phenyl group or a substituted phenyl group having chlorine atom(s), methyl group(s) or methoxy group(s) as the substituent(s), further R.sup.1 and R.sup.2 may form a single ring containing one or two hetero atoms including the adjacent nitrogen atom; R.sup.3 is a hydrogen atom, a lower alkyl group or a phenyl group; R.sup.4 is a substituted phenyl group having at least one acetyl group as a substituent thereon; with a pharmaceutically acceptable carrier.

2. Composition of claim 1, wherein said compound is 1,1,3-trimethyl-5-(4-acetylphenyl)biuret.